Moderna's Q2 report expected uneventful; key focus on COVID vaccine demand and Phase III melanoma data.

Moderna is set to report its Q2 results on July 31, with expectations of a modest revenue decline due to seasonal COVID-19 vaccine demand. Jefferies forecasts a loss of $1.99 per share on about $100 million revenue, down from Q1's $389 million. Investors are keenly watching the Phase III melanoma vaccine data, a potential catalyst for the stock, along with other pipeline updates like flu and norovirus vaccines. The company aims for 2026 revenue growth up to 10%, supported by international partnerships and stabilized US COVID sales.